Dev.) value was 5.75 ±1.69 L. The PPK of ipilimumab was studied in participants with advanced melanoma in 4 Phase 2, 1 Phase 3, and 1 Phase 1 studies. The PPK analysis demonstrated that the PK of ipilimumab was linear, the exposures were dose proportional across the tested dose range of 0.3 to 10 mg/kg, and the model parameters were time invariant, similar to those determined by noncompartmental analyses. Additional details are provided in the current version of the ipilimumab IB.